Chronic Limb Remote Ischemic Conditioning may have an Antihypertensive Effect in Patients with Hypertension

Wenting Guo1, Changhong Ren2,3, Bowei Zhang1

  • 11Department of Neurology, Xuanwu Hospital, Capital Medical University, Beijing, China.

Aging and Disease
|December 9, 2021
PubMed

Insights

Limb remote ischemic conditioning (LRIC) may lower blood pressure by activating protective bodily mechanisms. This review explores LRIC

Area of Science:

  • Cardiovascular Research
  • Nephrology
  • Neurology

Background:

  • Hypertension is a primary global risk factor for morbidity and mortality.
  • Current blood pressure control rates remain suboptimal despite available treatments.
  • Novel therapeutic strategies are needed to manage hypertension effectively.

Purpose of the Study:

  • To systematically review existing literature on limb remote ischemic conditioning (LRIC) and its effect on blood pressure.
  • To investigate the potential antihypertensive effects of LRIC.
  • To elucidate the underlying mechanisms through which LRIC may influence blood pressure.

Main Methods:

  • Systematic literature review of studies investigating LRIC and blood pressure.
  • Analysis of reported blood pressure changes in response to LRIC interventions.
  • Examination of proposed mechanisms of action for LRIC.

Main Results:

  • Existing studies report controversial findings regarding the antihypertensive effects of LRIC.
  • LRIC involves autonomic nervous system regulation, humoral factors, endothelial function, and immune modulation.
  • These mechanisms theoretically support a potential blood pressure-lowering effect of LRIC.

Conclusions:

  • LRIC presents a potential novel therapeutic approach for hypertension.
  • Further research is warranted to clarify the efficacy and mechanisms of LRIC in blood pressure management.
  • LRIC may offer a non-pharmacological strategy to reduce the burden of hypertensive disease.

Related Concept Videos

Heart Failure Drugs: Inhibitors of Renin-Angiotensin System01:26

Heart Failure Drugs: Inhibitors of Renin-Angiotensin System

The activation of the sympathetic nervous system and the renin-angiotensin-aldosterone system (RAAS) contributes to cardiac remodeling, and inhibiting the RAAS is a pharmacological target in heart failure management. As a result, neurohumoral modulation is a crucial treatment principle for managing heart failure. This approach involves using medications like ACE inhibitors (ACEIs), angiotensin receptor blockers (ARBs), β-blockers, mineralocorticoid receptor antagonists (MRAs), and neutral...
558
Peripheral Artery Disease III: Interprofessional Care01:27

Peripheral Artery Disease III: Interprofessional Care

Peripheral Artery Disease (PAD) is characterized by narrowed arteries that diminish blood flow to the extremities. Effective management of PAD requires an interprofessional approach involving various healthcare professionals. The critical aspects of interprofessional care for PAD patients focus on risk factor modification, drug therapy, exercise therapy, nutrition therapy, critical limb ischemia care, and interventional radiology and surgical procedures.The primary treatment goal for PAD...
50
Antihypertensive Drugs: Direct Renin Inhibitors01:25

Antihypertensive Drugs: Direct Renin Inhibitors

The renin-angiotensin-aldosterone system (RAAS) is an intricate physiological pathway involving numerous enzymes and hormones, including renin, angiotensin-converting enzyme (ACE), angiotensin I and II, and aldosterone. Imbalances within this system increase the production of angiotensin II and aldosterone. Increased angiotensin II levels promote vasoconstriction and blood pressure elevation. Concurrently, higher aldosterone levels stimulate sodium and water reabsorption in the kidneys,...
890
Antihypertensive Drugs: Potassium-Sparing Diuretics01:28

Antihypertensive Drugs: Potassium-Sparing Diuretics

Liddle syndrome is a genetically inherited form of hypertension characterized by the overactivity of epithelial sodium channels in the nephron, the functional unit of the kidney. This heightened activity leads to increased sodium reabsorption and excessive excretion of potassium. To counteract this, potassium-sparing diuretics such as amiloride are used. They function by blocking these sodium channels, thereby reducing the influx of sodium into the epithelial cells and minimizing the loss of...
901
Antihypertensive Drugs: Angiotensin-Converting Enzyme Inhibitors01:30

Antihypertensive Drugs: Angiotensin-Converting Enzyme Inhibitors

Angiotensin-converting enzyme (ACE), a vital component of the renin-angiotensin-aldosterone system, is abundant in lung endothelial cells. ACE converts the inactive decapeptide, angiotensin I, into the active octapeptide, angiotensin II. This potent vasoconstrictor narrows blood vessels, increasing resistance to blood flow and elevating blood pressure. Angiotensin II also stimulates aldosterone production, encouraging kidney cells to reabsorb more sodium and water from urine, thereby increasing...
1.0K
Hypertension IV: Drug Therapy and Lifestyle Modifications01:28

Hypertension IV: Drug Therapy and Lifestyle Modifications

Multiple classes of antihypertensive medications are employed in treating hypertension. The most commonly recommended first-line treatments include:Thiazide Diuretics, such as chlorthalidone, increase sodium and water excretion from the body, reducing blood volume and blood pressure.Angiotensin-converting enzyme inhibitors, like lisinopril, block the conversion of angiotensin I to II, a potent vasoconstrictor lowering blood pressure.Angiotensin II Receptor Blockers (ARBs) prevent angiotensin II...
101